US FDA approves Shire's Gaucher's therapy Vpriv
This article was originally published in Scrip
Executive Summary
The US FDA has approved Shire's Vpriv (velaglucerase alfa) for the treatment of type I Gaucher's disease, the most prevalent type of the rare lysosomal storage disease.